<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03401580</url>
  </required_header>
  <id_info>
    <org_study_id>EMS0317</org_study_id>
    <nct_id>NCT03401580</nct_id>
  </id_info>
  <brief_title>Efficacy of Fixed-doses of Antihypertensive and Statin Drugs</brief_title>
  <official_title>Clinical Trial to Compare the Efficacy and Safety of Fixed-doses of VIENA II in Participants With Hypertension and Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of different fixed-dose combination of
      Viena II in treatment of hypertension and dyslipidemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Fase II, national, multicenter, randomized, double-blind.

        -  Maximal duration: 8 weeks;

        -  04 visits;

        -  Safety and efficacy evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2019</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of systemic blood pressure measured between the first visit and last visit</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of reduction of LDL-c between the first visit and the last visit.</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events recorded during the study</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">276</enrollment>
  <condition>Hypertension</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Viena II - 160/10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed-dose, 160mg +10 mg, orally, once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Viena II - 190/10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed-dose, 190mg + 10 mg, orally, once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Viena II - 160/12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed-dose, 160mg + 12 mg, orally, once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Viena II - 190/12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed-dose, 190mg + 12 mg, orally, once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Viena II 160/10</intervention_name>
    <description>once daily</description>
    <arm_group_label>Viena II - 160/10</arm_group_label>
    <other_name>Viena II fixed dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Viena II 190/10</intervention_name>
    <description>once daily</description>
    <arm_group_label>Viena II - 190/10</arm_group_label>
    <other_name>Viena II fixed dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Viena II 160/12</intervention_name>
    <description>once daily</description>
    <arm_group_label>Viena II - 160/12</arm_group_label>
    <other_name>Viena II fixed dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Viena II 190/12</intervention_name>
    <description>once daily</description>
    <arm_group_label>Viena II - 190/12</arm_group_label>
    <other_name>Viena II fixed dose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants of both sexes aged between 18 and 65 years;

          -  Participants diagnosed with uncontrolled hypertension (stage 1), according VII
             Brazilian Guideline of Hypertension;

          -  Participants diagnosed with dyslipidemia, according to the V Brazilian Guidelines on
             Dyslipidemia and Prevention of Atherosclerosis;

          -  Signed consent.

        Exclusion Criteria:

          -  Participants with a previous diagnosis of familial hypercholesterolemia (homozygous);

          -  Concomitant use of angiotensin II receptor blocker (ARB) or inhibitor of angiotensin
             converting enzyme (ACE);

          -  Participants with total cholesterol (TC) above 500 mg / dL or triglyceride (TG) above
             500 mg / dL;

          -  Participants with hypertension (stage 2 or 3) according VII Brazilian Guideline of
             Hypertension;

          -  History of congestive heart failure (CHF) functional class III or IV (NYHA);;

          -  Any clinical, laboratory and electrocardiographic that, in the judgment of the
             investigator, may interfere with the safety of research participants;

          -  Creatine phosphokinase (CPK) levels above the established laboratory normal range;

          -  Transaminases (ALT and ASL) serum above 2 times the established laboratory normal
             range;

          -  Body mass index (BMI) ≥35 kg / m²;

          -  Immunocompromised participants (eg.: malignancies, patients with Acquired
             Immunodeficiency Syndrome etc);

          -  Chronic use of drugs that may interact with the drugs of the study;

          -  History hypersensitivity to the active ingredients used in the study;

          -  Pregnancy or risk of pregnancy and lactating patients;

          -  History of alcohol abuse or illicit drug use;

          -  Participation in clinical trial in the year prior to this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Monalisa F.B. Oliveira, MD</last_name>
    <phone>+551938879851</phone>
    <email>pesquisa.clinica@ems.com.br</email>
  </overall_contact>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2018</study_first_submitted>
  <study_first_submitted_qc>January 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

